SOUTH SAN FRANCISCO, Calif., Dec. 7, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson's presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif.
Dr. Johnson's presentation, "Optimization of Antibody Discovery from Mouse Repertoires Using Microfluidics, Deep Sequencing, and Yeast Display," will discuss how Surge technology can be used to quickly and comprehensively characterize mouse repertoires, enabling optimization of immunization campaigns for challenging immuno-oncology targets.
"We are pushing our technology to explore new frontiers in antibody discovery," said Dr. Johnson. "In my presentation, I discuss how conventional technologies only scratch the surface of the mouse repertoire, making it difficult to characterize and optimize mouse immunization strategies. We now routinely discover diverse panels of fully human, natively paired antibody drug candidates from various kinds of challenging disease targets."
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
Corporate Communications Contact:
Senior Vice President
SOURCE GigaGen Inc.